StemoniX has raised $ 14.4 m in series B funding to develop its stem cell - based chip - on - a - chip technology . The investment was led by Brightstone Venture Capital with funding from Crescent ##stone Partners , SEED San partners and new partners including Alumni Ventures Group and the Mayo Clinic . StemoniX uses induced pluripotent stem cells to generate functioning human micro - organisms which can be used to predict drug interactions in a manner that 's more efficient than traditional animal and human testing . The company announced it will use the funding to expand its commercial operations and develop new products and services .
StemoniX has raised $14.4m in series B funding to develop its stem cell-based organ-on-a-chip technology. The investment was led by Brightstone Venture Capital with support from Crescent Ridge Partners, SEED San Diego and new partners including Alumni Ventures Group and the Mayo Clinic. StemoniX uses induced pluripotent stem cells to build functioning human micro-organs which can be used to predict drug interactions in a process that's more efficient than traditional animal and human testing. The company announced it will use the funding to expand its commercial operations and develop new products and services.